NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.406) was uploaded to the NHS England Website on Thursday 6, August 2026.
The following changes have been introduced:
Acalabrutinib in combination bendamustine and rituximab (ACA4)
Acalabrutinib in combination with bendamustine and rituximab for UNTREATED mantle cell lymphoma when an autologous stem cell transplant is UNSUITABLE where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Acalabrutinib in combination with venetoclax (ACA5)
Acalabrutinib in combination with venetoclax for the 1st line treatment of previously untreated chronic lymphocytic leukaemia where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Gilteritinib (GILT2)
For the treatment of relapsed/refractory FLT3 mutation positive acute myeloid leukaemia in POST PUBESCENT CHILDREN where the following criteria have been met
Medicines For Children form created for TA642
NA (NHSE Policy 2268)
NA
Clinicial Commissioning Policy: added directly into routine commissioning - section B of list
NA (NHSE Policy 2432)
NA
Clinicial Commissioning Policy: added directly into routine commissioning - section B of list
Belantamab mafodotin in combination with bortezomib and dexamethasone (BELA1)
Belantamab mafodotin in combination with bortezomib and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients where the following criteria have been met
Moved into routine commissioning - section B of list
Encorafenib in combination with binimetinib (ENC3)
For the first line treatment of metastatic BRAF V600 mutation positive non-small cell lung cancer where the following criteria have been met
Moved into routine commissioning - section B of list
NA (LISO2a/b)
NA
Moved into routine commissioning - section B of list
Pembrolizumab (PEMB34)
Pembrolizumab for resectable, locally advanced, head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a combined positive score of 1 or more where the following criteria have been met
Moved into routine commissioning - section B of list
Ripretinib (RIP1)
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 more kinase inhibitors where the following criteria have been met
Moved into routine commissioning - section B of list
Vorasidenib (VOR1)
For treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in patients aged 12 years and over where the following criteria have been met
Moved into routine commissioning - section B of list
Zanidatamab (ZANI1)
For the treatment of HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment where the following criteria have been met
Moved into routine commissioning - section B of list
Amivantamab in combination with lazertinib (AMI1)
For the first line treatment of locally advanced or metastatic non-small cell lung cancer in adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations where the following criteria have been met
Treatment criterion (#1, 3 and 4) updated
Dostarlimab (DOS1)
Dostarlimab monotherapy for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) recurrent/advanced endometrial carcinoma after prior platinum-based chemotherapy where the following criteria have been met
Treatment criterion (#1, 8, 10 and 11) updated
Inotuzumab ozogamicin (INO2)
The treatment of relapsed/refractory Philadelphia positive and negative B cell precursor acute lymphoblastic leukaemia in CHILD patients where all the following criteria are met:
Treatment criterion (#4, 6, 7 and 10) updated
Isatuximab in combination with pomalidomide and dexamethasone (ISA1)
Isatuximab in combination with pomalidomide and dexamethasone for the 4th line treatment of adult patients with relapsed/refractory multiple myeloma where the following criteria have been met
Treatment criterion (#1, 9 and 14) updated
NA (NIV8)
NA
Treatment criterion (#1 and 5) updated
Nivolumab and ipilimumab (NIV18)
Nivolumab in combination with ipilimumab for treating advanced melanoma
Treatment criterion (#1 and 4) updated
Nivolumab in combination with relatlimab (Opdualag ®) (NIVREL1)
As first immunotherapy for treating unresectable or metastatic melanoma patients aged 12 years or more where the following criteria have been met
Treatment criterion (#1, 5 and 10) updated
Pembrolizumab (PEMB9a)
Pembrolizumab monotherapy for treating unresectable or advanced malignant melanoma (form a): REGISTRATION OF START OF PEMBROLIZUMAB MONOTHERAPY OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED PEMBROLIZUMAB MONOTHERAPY This form comes in 3 parts. 1. The first part is for patients who are either scheduled to commence pembrolizumab monotherapy or who commenced and continue to receive pembrolizumab monotherapy. 2. The second part of the form which must use the same unique Blueteq identifier is for those benefitting patients who choose to electively discontinue pembrolizumab after 2 or more years of treatment; this second part (patient details be automatically entered) will only appear once the first part of the form is approved and should be completed at the time of elective discontinuation of pembrolizumab. 3. The third part of the form which must use the same unique Blueteq identifier is for those patients registered as having electively and previously stopped pembrolizumab and in whom there is disease progression for which the clinician wishes to re-commence pembrolizumab; this third part of the form (patient details will automatically entered) will only appear once
Treatment criterion (#1 and 5) updated
Pembrolizumab (PEMB16)
For relapsed/refractory classical Hodgkin lymphoma in patients aged 3 years and older who have been treated with stem cell transplantation but never previously received brentuximab vedotin where the following criteria have been met
Treatment criterion (#1, 8, 10 and 11) updated